Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

Type 1 Diabetes Clinical Trial

Official title:

Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05224258
• Other study ID #: CIP336
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 17, 2022
• Est. completion date: July 2024

Study information

• Verified date: April 2024
• Source: Medtronic Diabetes
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.

Description:

This global study is a multi-center, single arm study in insulin-requiring adult and pediatric subjects with type 1 diabetes on the MiniMed 780G system using Fiasp insulin as well as Medtronic Extended infusion set and reservoir. The run-in period and study period will be approximately 120 days long.

A total of up to 250 subjects with insulin-requiring type 1 diabetes age 7-80 will be enrolled at up to 25 investigational centers across the United States, Canada, and Australia in order to have 200 subjects enter the study period. Up to 125 subjects will be enrolled in the pediatric age group (7-17 years of age), up to 125 in the adult age group (18 years or older)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 240
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 80 Years

Eligibility

INCLUSION CRITERIA:

1. Age 7 - 80 years at time of screening.

2. Has a clinical diagnosis of type 1 diabetes:

1. 14 - 80 years of age: A clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.

2. 7 - 13 years of age: A clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.

3. Does not require a legally authorized representative to consent on their behalf due to mental or intellectual disability.

4. Subject or parent/caregiver is literate and able to read one of the languages offered in the pump.

5. Subject and/or legally authorized representative is willing to provide informed consent for participation.

6. Is willing to perform fingerstick blood glucose measurements as needed.

7. Is willing to wear the system continuously throughout the study.

8. Must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units and maximum total daily dose of 250 units or less.

9. Has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by Central Lab) at time of screening visit.

Note: All HbA1c blood specimens will be sent to and tested by a National Glycohemoglobin Standardization Program (NGSP) certified Central Laboratory. HbA1c testing must follow NGSP standards.

10. Has thyroid-stimulating hormone (TSH) in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.

11. Uses pump therapy for greater than 6 months prior to screening (with or without CGM experience)

12. Is willing to upload data from the study pump, must have Internet access, and a computer system, or compatible smartphone that meets the requirements for uploading the study pump.

13. Is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations as required during the run-in period:

1. Humalog (insulin lispro injection)

2. NovoLog/NovoRapid (insulin aspart injection)

14. Is willing to take Fiasp insulin during the study period (supplied via Sponsor).

EXCLUSION CRITERIA:

1. Has hypersensitivity to insulin aspart or one of the excipients in Fiasp.

2. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:

1. Medical assistance (i.e., Paramedics, Emergency Room [ER] or Hospitalization)

2. Coma

3. Seizures

3. Has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes.

4. Has had DKA in the last 6 months prior to screening visit.

5. Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.

6. Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).

7. Is female of child-bearing potential and result of pregnancy test is positive at screening.

8. Is sexually active female of child-bearing potential and is not using a form of contraception deemed reliable by the investigator.

9. Is female and plans to become pregnant during the course of the study.

10. Is being treated for hyperthyroidism at time of screening.

11. Has diagnosis of adrenal insufficiency.

12. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.

13. Is using hydroxyurea at time of screening or plans to use it during the study.

14. Is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks.

15. Is currently abusing illicit drugs.

16. Is currently abusing marijuana.

17. Is currently abusing prescription drugs.

18. Is currently abusing alcohol.

19. Using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening.

20. Has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator.

21. Has elective surgery planned that requires general anesthesia during the course of the study.

22. Has sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening.

23. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation.

24. Is diagnosed with current eating disorder such as anorexia or bulimia.

25. Has been diagnosed with chronic kidney disease that results in chronic anemia.

26. Has a hematocrit that is below the normal reference range of lab used.

27. Is on dialysis.

28. Has serum creatinine of >2 mg/dL.

29. Has celiac disease that is not adequately treated as determined by the investigator.

30. Has had any of the following cardiovascular events within 1 year of screening:

myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.

31. Has had history of cardiovascular event 1 year or more from the time of screening without

1. a normal EKG and stress test within 6 months prior to screening or during screening or

2. clearance from a qualified physician prior to receiving the study devices if there is an abnormal EKG or stress test.

32. Has 3 or more cardiovascular risk factors listed below without a normal EKG within 6 months prior to screening or during screening or clearance from a qualified physician if there is an abnormal EKG:

• Age >35 years

• Type 1 diabetes of >15 years' duration

• Presence of any additional risk factor for coronary artery disease

• Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)

• Presence of peripheral vascular disease

• Presence of autonomic neuropathy

33. Is a member of the research staff involved with the study.

34. Has used a MiniMed 780G pump prior to screening.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Device:
• MiniMed 780G System
780G System used with Insulin Fiasp® (Insulin Aspart Injection)

Locations

Country	Name	City	State
Australia	John Hunter Childrens Hospital	New Lambton	New South Wales
Canada	Alberta Children's Hospital Research Institute	Calgary	Alberta
Canada	LMC Clinical Research	Toronto	Ontario
United States	Atlanta Diabetes Associates	Atlanta	Georgia
United States	Barbara Davis Center for Diabetes	Aurora	Colorado
United States	Barry J Reiner MD, LLC	Baltimore	Maryland
United States	Valley Research	Fresno	California
United States	Physicians East	Greenville	North Carolina
United States	Rocky Mountain Clinical Research	Idaho Falls	Idaho
United States	The Docs, LLC	Las Vegas	Nevada
United States	Medical Investigations, Inc.	Little Rock	Arkansas
United States	Rainier Clinical Research Center	Renton	Washington
United States	Endocrine Research Solutions	Roswell	Georgia
United States	Sutter Institute for Medical Research	Sacramento	California
United States	Diabetes and Glandular Disease Clinic, P.A.	San Antonio	Texas
United States	Rady's Children's Hospital	San Diego	California
United States	MultiCare Institute for Research & Innovation	Tacoma	Washington
United States	University of South Florida	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Diabetes

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Safety Endpoint for Age 18-80 - Change in HbA1c	Age 18-80: The overall mean change in HbA1c from baseline to end of 3-month study period. Non-inferiority test.	3 months
Primary	Primary Safety Endpoint for Age 7-17 - Change in HbA1c	Age 7-17: The overall mean change in HbA1c from baseline to end of 3-month study period. Non-inferiority test.	3 months
Primary	Primary Effectiveness Endpoint for Age 18-80 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L])	Age 18-80: The mean % of time in range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]). Non-inferiority test.	3 months
Primary	Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L])	Age 7-17: The mean % of time in range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]). Non-inferiority test.	3 months
Secondary	Secondary Effectiveness Endpoint 1 for Age 18-80 - Percent of Time in Hypoglycemia (< 54 mg/dL [3.0 mmol/L])	Age 18-80: The mean % of time in hypoglycemia (< 54 mg/dL [3.0 mmol/L]). Non-inferiority test.	3 months
Secondary	Secondary Effectiveness Endpoint 1 for Age 7-17 - Percent of Time in Hypoglycemia (< 54 mg/dL [3.0 mmol/L])	Age 7-17: The mean % of time in hypoglycemia (< 54 mg/dL [3.0 mmol/L]). Non-inferiority test.	3 months
Secondary	Secondary Effectiveness Endpoint 2 for Age 18-80 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L])	Age 18-80: The mean % of time in range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]).Superiority test.	3 months
Secondary	Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L])	Age 7-17: The mean % of time in range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]).Superiority test.	3 months